Long-Term Safety of Tofacitinib for Treatment of Moderate-to-Severe Ulcerative Colitis: Three Years of Korean National Data

Ulcerative colitis (UC) requires long-term treatment. Tofacitinib, a JAK inhibitor approved for UC, raises safety concerns regarding serious adverse events (SAEs) such as thromboembolism, major adverse cardiovascular events (MACEs), and opportunistic infections. This study aimed to evaluate the long...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of Korean medical science Vol. 40; no. 39; pp. e259 - 9
Main Authors:	Song, Eun Mi, Seo, Gi Hyeon, Jung, Sung Hoon
Format:	Journal Article
Language:	English
Published:	Korea (South) 대한의학회 13.10.2025
Subjects:	Adult Aged Colitis, Ulcerative - drug therapy Colitis, Ulcerative - pathology Databases, Factual Female Herpes Zoster - epidemiology Humans Incidence Janus Kinase Inhibitors - adverse effects Janus Kinase Inhibitors - therapeutic use Male Middle Aged Piperidines - adverse effects Piperidines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Republic of Korea - epidemiology Risk Factors Severity of Illness Index Thromboembolism - epidemiology Thromboembolism - etiology Tumor Necrosis Factor Inhibitors - adverse effects Tumor Necrosis Factor Inhibitors - therapeutic use Young Adult 의학일반 Republic of Korea Cardiovascular Diseases Tofacitinib Ulcerative Colitis Infections Inflammatory Bowel Disease Safety Thromboembolism Korea
ISSN:	1011-8934, 1598-6357, 1598-6357
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!